APA (7th ed.) Citation

Camporeale, A., Kudrow, D., Sides, R., Wang, S., Van Dycke, A., Selzler, K. J., & Stauffer, V. L. (2018). A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC neurology, 18(1), 188-12. https://doi.org/10.1186/s12883-018-1193-2

Chicago Style (17th ed.) Citation

Camporeale, Angelo, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler, and Virginia L. Stauffer. "A Phase 3, Long-term, Open-label Safety Study of Galcanezumab in Patients with Migraine." BMC Neurology 18, no. 1 (2018): 188-12. https://doi.org/10.1186/s12883-018-1193-2.

MLA (9th ed.) Citation

Camporeale, Angelo, et al. "A Phase 3, Long-term, Open-label Safety Study of Galcanezumab in Patients with Migraine." BMC Neurology, vol. 18, no. 1, 2018, pp. 188-12, https://doi.org/10.1186/s12883-018-1193-2.